Traws Pharma Inc Market Cap ($4.64 Million)
Market Cap & Net Worth: Traws Pharma Inc (TRAW)
Traws Pharma Inc market cap. Traws Pharma Inc (NASDAQ:TRAW) has a market capitalization of $4.64 Million ($4.64 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28661 globally and #5894 in its home market, demonstrating a -11.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Traws Pharma Inc's stock price $0.30 by its total outstanding shares 15368277 (15.37 Million). Also see Traws Pharma Inc (TRAW) cash conversion ratio for how efficiently the company converts equity into cash flow.
Traws Pharma Inc Market Cap History (2015–2026)
Traws Pharma Inc market cap history from 2015 to 2026. Data shows change from $827.12 Billion to $4.64 Million (-67.78% CAGR). Check latest Traws Pharma Inc stock price today for real-time trading data and today's change.
Index Memberships
Traws Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #824 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2637 of 3165 |
Weight: Traws Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Traws Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Traws Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore TRAW net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.22x
Traws Pharma Inc's market cap is 6.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.89x
Traws Pharma Inc's market cap is 1.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $196.23 Billion | $5.55 Million | -$19.67 Million | 35382.92x | N/A |
| 2017 | $129.67 Billion | $787.00K | -$24.09 Million | 164764.72x | N/A |
| 2018 | $12.16 Billion | $1.23 Million | -$20.57 Million | 9902.40x | N/A |
| 2019 | $2.21 Billion | $2.18 Million | -$21.50 Million | 1011.12x | N/A |
| 2020 | $2.68 Billion | $231.00K | -$25.16 Million | 11621.01x | N/A |
| 2021 | $979.73 Million | $226.00K | -$16.16 Million | 4335.08x | N/A |
| 2022 | $248.08 Million | $226.00K | -$18.96 Million | 1097.71x | N/A |
| 2023 | $286.46 Million | $226.00K | -$18.95 Million | 1267.54x | N/A |
| 2024 | $142.77 Million | $226.00K | -$54.67 Million | 631.73x | N/A |
| 2025 | $17.37 Million | $2.79 Million | $9.17 Million | 6.22x | 1.89x |
Competitor Companies of TRAW by Market Capitalization
Companies near Traws Pharma Inc in the global market cap rankings as of November 4, 2026. Also see Traws Pharma Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Traws Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Traws Pharma Inc (2015–2026)
Market capitalization of Traws Pharma Inc from 2015 to today. Between 2015 and today, Traws Pharma Inc's market cap moved from $827.12 Billion to $ 4.64 Million, with a yearly change of -67.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.64 Million | -73.27% |
| 2025 | $17.37 Million | -87.84% |
| 2024 | $142.77 Million | -50.16% |
| 2023 | $286.46 Million | +15.47% |
| 2022 | $248.08 Million | -74.68% |
| 2021 | $979.73 Million | -63.50% |
| 2020 | $2.68 Billion | +21.62% |
| 2019 | $2.21 Billion | -81.85% |
| 2018 | $12.16 Billion | -90.62% |
| 2017 | $129.67 Billion | -33.92% |
| 2016 | $196.23 Billion | -76.28% |
| 2015 | $827.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Traws Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.64 Million USD |
| MoneyControl | $4.64 Million USD |
| MarketWatch | $4.64 Million USD |
| marketcap.company | $4.64 Million USD |
| Reuters | $4.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more